Literature DB >> 34259608

Adipose Stem Cell-Derived Exosomes Ameliorate Chronic Rotator Cuff Tendinopathy by Regulating Macrophage Polarization: From a Mouse Model to a Study in Human Tissue.

Chongyang Wang1, Yao Zhang1, Guangcheng Zhang1, Weilin Yu1, Yaohua He2.   

Abstract

BACKGROUND: Chronic rotator cuff (RC) tendinopathy is one of the most prevalent causes of shoulder pain. Growing evidence suggests that macrophages play a significant role in the proinflammatory response, resolution of inflammation, and tissue healing of tendinopathy. In particular, enhancement of M2 macrophage (M2φ) activity contributes to the accelerated healing of tendinopathy. Therefore, a treatment that enhances M2φ polarization would be useful for patients with this common musculoskeletal disorder.
PURPOSE: To investigate whether adipose stem cell-derived exosomes (ASC-Exos) enhance M2φ polarization and ameliorate chronic RC tendinopathy. STUDY
DESIGN: Controlled laboratory study.
METHODS: First, we compared the effects of ASC-Exos on polarization of mouse bone marrow-derived macrophages between a classically activated phenotype (M1φ) and an alternatively activated phenotype (M2φ) in vitro. In total, 72 C57BL/6 mice were assigned to normal cage activity (n = 24) or 5 weeks of treadmill overuse (n = 48). The supraspinatus tendon of each treadmill overuse mouse was treated with ASC-Exos (n = 24) or saline (n = 24). Histological and biomechanical outcomes were assessed 4 weeks after treatment. Finally, tissue samples from human patients with RC tendinopathy were obtained to assay the effect of ASC-Exos on the M1φ/M2φ balance in tissue-resident macrophages.
RESULTS: ASC-Exos inhibited M1φ polarization and augmented M2φ polarization in vitro and in vivo. Mice in the ASC-Exos group showed less severe pathological changes than those in the saline group, including less cellular infiltration, disorganization of collagen, and ground substance deposition. The modified Bonar score of the ASC-Exos group (mean ± SD, 7.68 ± 1.03) was significantly lower than that of the saline group (9.81 ± 0.96; P < .05). Furthermore, the maximum failure load was significantly higher in the ASC-Exos group than in the saline group (4.23 ± 0.66 N vs 3.86 ± 0.65 N; P < .05), as was stiffness (3.38 ± 0.34 N/m vs 2.68 ± 0.49 N/m; P < .05).
CONCLUSION: ASC-Exos-mediated polarization balance of M1φ/M2φ contributes to the amelioration of chronic RC tendinopathy. Regulation of the M1φ/M2φ balance could be a new target for the treatment of chronic RC tendinopathy. CLINICAL RELEVANCE: Administration of ASC-Exos is a cell-free approach that may become a novel treatment option for chronic RC tendinopathy and should be explored further.

Entities:  

Keywords:  adipose stem cell–derived exosomes; inflammation; macrophage; rotator cuff tendinopathy

Year:  2021        PMID: 34259608     DOI: 10.1177/03635465211020010

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  4 in total

1.  The Therapeutic Effect of iMSC-Derived Small Extracellular Vesicles on Tendinopathy Related Pain Through Alleviating Inflammation: An in vivo and in vitro Study.

Authors:  Zhaochen Zhu; Renzhi Gao; Teng Ye; Kai Feng; Juntao Zhang; Yu Chen; Zongping Xie; Yang Wang
Journal:  J Inflamm Res       Date:  2022-03-01

Review 2.  Advances in Stem Cell Therapies for Rotator Cuff Injuries.

Authors:  Hao-Nan Wang; Xiao Rong; Lu-Ming Yang; Wei-Zhong Hua; Guo-Xin Ni
Journal:  Front Bioeng Biotechnol       Date:  2022-05-25

Review 3.  The Therapeutic Potential of Exosomes in Soft Tissue Repair and Regeneration.

Authors:  Rou Wan; Arif Hussain; Atta Behfar; Steven L Moran; Chunfeng Zhao
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

4.  Disulfiram Suppressed Peritendinous Fibrosis Through Inhibiting Macrophage Accumulation and Its Pro-inflammatory Properties in Tendon Bone Healing.

Authors:  Qi Zhou; Wei Wang; Fujun Yang; Hao Wang; Xiaodong Zhao; Yiqin Zhou; Peiliang Fu; Yaozeng Xu
Journal:  Front Bioeng Biotechnol       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.